NVTA has been the topic of several other reports. Cowen lowered shares of Invitae from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 26th. JPMorgan Chase & Co. lowered shares of Invitae from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 10th. William Blair reissued a “market perform” rating on shares of Invitae in a research report on Tuesday, November 8th. Credit Suisse Group began coverage on shares of Invitae in a research report on Wednesday, August 24th. They issued an “underperform” rating on the stock. Finally, Cowen increased their price objective on shares of Invitae to $2.80 in a research report on Tuesday, November 15th. Four analysts have rated the stock with a sell rating and nine have issued a hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.04.
Invitae Stock Performance
NYSE NVTA opened at $2.84 on Friday. The company has a current ratio of 6.44, a quick ratio of 6.18 and a debt-to-equity ratio of 10.03. The firm’s fifty day moving average price is $2.65 and its two-hundred day moving average price is $2.99. Invitae has a 1 year low of $1.83 and a 1 year high of $19.79. The firm has a market capitalization of $689.84 million, a P/E ratio of -0.21 and a beta of 1.59.
Institutional Trading of Invitae
Several large investors have recently modified their holdings of the stock. Financial Advocates Investment Management acquired a new stake in Invitae in the 3rd quarter valued at $206,000. Operose Advisors LLC acquired a new stake in Invitae in the 1st quarter valued at $32,000. AdvisorNet Financial Inc grew its position in Invitae by 61.0% in the 3rd quarter. AdvisorNet Financial Inc now owns 10,000 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 3,788 shares during the period. Credit Agricole S A acquired a new stake in Invitae in the 3rd quarter valued at $25,000. Finally, Clearwater Capital Advisors LLC acquired a new stake in Invitae in the 1st quarter valued at $82,000. Institutional investors and hedge funds own 88.27% of the company’s stock.
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.